(Q35827833)

English

Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration

scientific article published on 28 June 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

0 references

Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Kurz

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

B Van Baelen

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

28 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Dementia and Geriatric Cognitive Disorders

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

217-226

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized double blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

A Standardized Memory Scale for Clinical Use

1 reference

https://api.crossref.org/works/10.1159%2F000079388

21 January 2018

Identifiers

10.1159/000079388

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35827833&oldid=1599649108"